126 related articles for article (PubMed ID: 15762041)
1. Loss of heterozygosity at the SS receptor type 5 locus in human GH- and TSH-secreting pituitary adenomas.
Filopanti M; Ballarè E; Lania AG; Bondioni S; Verga U; Locatelli M; Zavanone LM; Losa M; Gelmini S; Peri A; Orlando C; Beck-Peccoz P; Spada A
J Endocrinol Invest; 2004 Nov; 27(10):937-42. PubMed ID: 15762041
[TBL] [Abstract][Full Text] [Related]
2. Genetic abnormalities of somatostatin receptors in pituitary tumors.
Lania A; Mantovani G; Spada A
Mol Cell Endocrinol; 2008 May; 286(1-2):180-6. PubMed ID: 17913341
[TBL] [Abstract][Full Text] [Related]
3. Human adrenocorticotropin-secreting pituitary adenomas show frequent loss of heterozygosity at the glucocorticoid receptor gene locus.
Huizenga NA; de Lange P; Koper JW; Clayton RN; Farrell WE; van der Lely AJ; Brinkmann AO; de Jong FH; Lamberts SW
J Clin Endocrinol Metab; 1998 Mar; 83(3):917-21. PubMed ID: 9506748
[TBL] [Abstract][Full Text] [Related]
4. Loss of heterozygosity of the MEN1 gene in a large series of TSH-secreting pituitary adenomas.
Asteria C; Anagni M; Persani L; Beck-Peccoz P
J Endocrinol Invest; 2001 Nov; 24(10):796-801. PubMed ID: 11765049
[TBL] [Abstract][Full Text] [Related]
5. Somatostatin receptor subtype gene expression in pituitary adenomas.
Miller GM; Alexander JM; Bikkal HA; Katznelson L; Zervas NT; Klibanski A
J Clin Endocrinol Metab; 1995 Apr; 80(4):1386-92. PubMed ID: 7714115
[TBL] [Abstract][Full Text] [Related]
6. Molecular screening of pituitary adenomas for gene mutations and rearrangements.
Herman V; Drazin NZ; Gonsky R; Melmed S
J Clin Endocrinol Metab; 1993 Jul; 77(1):50-5. PubMed ID: 8100831
[TBL] [Abstract][Full Text] [Related]
7. GH-secreting pituitary adenomas infrequently contain inactivating mutations of PRKAR1A and LOH of 17q23-24.
Yamasaki H; Mizusawa N; Nagahiro S; Yamada S; Sano T; Itakura M; Yoshimoto K
Clin Endocrinol (Oxf); 2003 Apr; 58(4):464-70. PubMed ID: 12641630
[TBL] [Abstract][Full Text] [Related]
8. Human pituitary adenomas show no loss of heterozygosity at the retinoblastoma gene locus.
Zhu J; Leon SP; Beggs AH; Busque L; Gilliland DG; Black PM
J Clin Endocrinol Metab; 1994 Apr; 78(4):922-7. PubMed ID: 8157722
[TBL] [Abstract][Full Text] [Related]
9. Endocrine and immunohistochemical studies on thyrotropin (TSH)-secreting pituitary adenomas: responses of TSH, alpha-subunit, and growth hormone to hypothalamic releasing hormones and their distribution in adenoma cells.
Kuzuya N; Inoue K; Ishibashi M; Murayama Y; Koide Y; Ito K; Yamaji T; Yamashita K
J Clin Endocrinol Metab; 1990 Nov; 71(5):1103-11. PubMed ID: 1699960
[TBL] [Abstract][Full Text] [Related]
10. Somatostatin and dopamine-somatostatin multiple ligands directed towards somatostatin and dopamine receptors in pituitary adenomas.
Saveanu A; Gunz G; Guillen S; Dufour H; Culler MD; Jaquet P
Neuroendocrinology; 2006; 83(3-4):258-63. PubMed ID: 17047391
[TBL] [Abstract][Full Text] [Related]
11. [New medical treatments in pituitary adenomas].
Drutel A; Caron P; Archambeaud F
Ann Endocrinol (Paris); 2008 Sep; 69 Suppl 1():S16-28. PubMed ID: 18954854
[TBL] [Abstract][Full Text] [Related]
12. A potential inhibitory role for the new truncated variant of somatostatin receptor 5, sst5TMD4, in pituitary adenomas poorly responsive to somatostatin analogs.
Durán-Prado M; Saveanu A; Luque RM; Gahete MD; Gracia-Navarro F; Jaquet P; Dufour H; Malagón MM; Culler MD; Barlier A; Castaño JP
J Clin Endocrinol Metab; 2010 May; 95(5):2497-502. PubMed ID: 20233783
[TBL] [Abstract][Full Text] [Related]
13. Somatostatin receptor subtype expression in human tumors.
Hofland LJ; Lamberts SW
Ann Oncol; 2001; 12 Suppl 2():S31-6. PubMed ID: 11762349
[TBL] [Abstract][Full Text] [Related]
14. Absence of somatostatin receptor type 2 A mutations and gip oncogene in pituitary somatotroph adenomas.
Petersenn S; Heyens M; Lüdecke DK; Beil FU; Schulte HM
Clin Endocrinol (Oxf); 2000 Jan; 52(1):35-42. PubMed ID: 10651751
[TBL] [Abstract][Full Text] [Related]
15. Somatostatin receptors on thyrotropin-secreting pituitary adenomas: comparison with the inhibitory effects of octreotide upon in vivo and in vitro hormonal secretions.
Bertherat J; Brue T; Enjalbert A; Gunz G; Rasolonjanahary R; Warnet A; Jaquet P; Epelbaum J
J Clin Endocrinol Metab; 1992 Aug; 75(2):540-6. PubMed ID: 1353505
[TBL] [Abstract][Full Text] [Related]
16. Screening for MEN1 tumor suppressor gene mutations in sporadic pituitary tumors.
Evans CO; Brown MR; Parks JS; Oyesiku NM
J Endocrinol Invest; 2000 May; 23(5):304-9. PubMed ID: 10882148
[TBL] [Abstract][Full Text] [Related]
17. The MEN-1 gene is rarely down-regulated in pituitary adenomas.
Asa SL; Somers K; Ezzat S
J Clin Endocrinol Metab; 1998 Sep; 83(9):3210-2. PubMed ID: 9745428
[TBL] [Abstract][Full Text] [Related]
18. Clinicopathological characteristics and therapeutic outcomes in thyrotropin-secreting pituitary adenomas: a single-center study of 90 cases.
Yamada S; Fukuhara N; Horiguchi K; Yamaguchi-Okada M; Nishioka H; Takeshita A; Takeuchi Y; Ito J; Inoshita N
J Neurosurg; 2014 Dec; 121(6):1462-73. PubMed ID: 25237847
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin receptor-specific analogs: effects on cell proliferation and growth hormone secretion in human somatotroph tumors.
Danila DC; Haidar JN; Zhang X; Katznelson L; Culler MD; Klibanski A
J Clin Endocrinol Metab; 2001 Jul; 86(7):2976-81. PubMed ID: 11443154
[TBL] [Abstract][Full Text] [Related]
20. Relevance of coexpression of somatostatin and dopamine D2 receptors in pituitary adenomas.
Saveanu A; Jaquet P; Brue T; Barlier A
Mol Cell Endocrinol; 2008 May; 286(1-2):206-13. PubMed ID: 18241980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
